AVP-786 Relieves Agitation in Alzheimer’s Patients, Preliminary Phase 3 Trial Results Show

AVP-786 Relieves Agitation in Alzheimer’s Patients, Preliminary Phase 3 Trial Results Show
AVP-786, an investigational oral therapy, significantly relieved agitated behaviors among patients with Alzheimer's dementia, according to preliminary data from a Phase 3 trial by Avanir Pharmaceuticals. The treatment candidate was designed as a second-generation version of Nuedexta, a two-drug combo approved for pseudobulbar affect. AVP-786 is a combination of dextromethorphan and quinidine — like Nuedexta — but it also contains deuterium, an isotope of hydrogen. AVP 786 is a combination product of deudextromethorphan hydrobromide and quinidine sulfate. Dextromethorphan is the component acting on the central nervous system (brain and spinal cord). It is also an over-the-counter cough suppressant that affects brain signals that trigger the cough reflex. Quinidine sulfate is a medicine that affects the way the heart beats and is used to treat abnormal heart rhythms. In this formulation, in a low dose, it helps increase the availability of dextromethorphan in the body by slowing its metabolism. It was given Fast Track designation in 2015 by the U.S. Food and Drug Administration (FDA) to possibly treat agitation in patients with Al
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *